Deep brain stimulation in Parkinson's disease patients and routine 6‐OHDA rodent models: Synergies and pitfalls.

Saved in:

Bibliographic Details
Title:	Deep brain stimulation in Parkinson's disease patients and routine 6‐OHDA rodent models: Synergies and pitfalls.
Authors:	Stefani, Alessandro (AUTHOR), Cerroni, Rocco (AUTHOR), Pierantozzi, Mariangela (AUTHOR), D'Angelo, Vincenza (AUTHOR), Grandi, Laura (AUTHOR), Spanetta, Matteo (AUTHOR), Galati, Salvatore (AUTHOR)
Source:	European Journal of Neuroscience. Apr2021, Vol. 53 Issue 7, p2322-2343. 22p. 3 Diagrams.
Subjects:	Subthalamic nucleus, Deep brain stimulation, Parkinson's disease, Basal ganglia diseases, Rodents, Basal ganglia
Abstract:	The history of deep brain stimulation for Parkinson's disease (PD) represented a paradigmatic cross‐talk between mammalian disease models and clinical evidence in humans. Fascinating were the results achieved by high frequency stimulation (HFS) into the subthalamic nucleus (STN) of MPTP‐treated primates. An analogous strategy relieved tremor and hypokinetic parameters in PD patients. The 6‐hydroxydopamine (6‐OHDA) rodent model has mastered decades of research, contributing to understanding of the PD pathology. However, this review wonders about the actual synergy between the routine neurotoxic models and PD patients underlying STN‐DBS. At first, some findings collected following 6‐OHDA, promoted dogmatic visions, as the wrong contention that suppression of STN glutamate was the key therapeutic player. Instead, changes of glutamate release are negligible in humans during transition to ON‐state. Besides, the imbalance of basal ganglia endogenous band frequencies, the beta (β) band increase and the cortical‐basal ganglia synchronization, undisputedly shared by models and PD patients, do not govern the whole spectrum of non‐motor PD signs, difficult to investigate in rodents. Furthermore, the tonic release of dopamine, inferred during HFS in rodents, was not replicated in humans. Finally, neurotoxic rodent models describe a 'pure' dopamine depletion sparing pathways crucial in parkinsonian phenotypes, that is, noradrenergic and cholinergic ones. Although the utilization of neurotoxic models is still providing major advancements, we pore over these contradictions and try to support possible amendments of neurotoxic models (advocating modern 'in vivo' approaches and recordings extending towards motor thalamus) for pursing the development of new DBS technology. [ABSTRACT FROM AUTHOR]
	Copyright of European Journal of Neuroscience is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database:	Psychology and Behavioral Sciences Collection

Description
Abstract:	The history of deep brain stimulation for Parkinson's disease (PD) represented a paradigmatic cross‐talk between mammalian disease models and clinical evidence in humans. Fascinating were the results achieved by high frequency stimulation (HFS) into the subthalamic nucleus (STN) of MPTP‐treated primates. An analogous strategy relieved tremor and hypokinetic parameters in PD patients. The 6‐hydroxydopamine (6‐OHDA) rodent model has mastered decades of research, contributing to understanding of the PD pathology. However, this review wonders about the actual synergy between the routine neurotoxic models and PD patients underlying STN‐DBS. At first, some findings collected following 6‐OHDA, promoted dogmatic visions, as the wrong contention that suppression of STN glutamate was the key therapeutic player. Instead, changes of glutamate release are negligible in humans during transition to ON‐state. Besides, the imbalance of basal ganglia endogenous band frequencies, the beta (β) band increase and the cortical‐basal ganglia synchronization, undisputedly shared by models and PD patients, do not govern the whole spectrum of non‐motor PD signs, difficult to investigate in rodents. Furthermore, the tonic release of dopamine, inferred during HFS in rodents, was not replicated in humans. Finally, neurotoxic rodent models describe a 'pure' dopamine depletion sparing pathways crucial in parkinsonian phenotypes, that is, noradrenergic and cholinergic ones. Although the utilization of neurotoxic models is still providing major advancements, we pore over these contradictions and try to support possible amendments of neurotoxic models (advocating modern 'in vivo' approaches and recordings extending towards motor thalamus) for pursing the development of new DBS technology. [ABSTRACT FROM AUTHOR]
ISSN:	0953816X
DOI:	10.1111/ejn.14950